β-adrenergic antagonists in hypertension: A review of the evidence

Annals of Pharmacotherapy

Volumn 43, Issue 12, 2009, Pages 2031-2043

  Warmack, T Scott ^a   Estes, Mark A ^a   Heldenbrand, Seth ^a   Franks, Amy M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

blocker; receptor antagonist; Antihypertensive therapy; Blood pressure; Hypertension

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL STIMULATING AGENT; CAPTOPRIL; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; HYDROCHLOROTHIAZIDE; LABETALOL; LACIDIPINE; LOSARTAN; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; OXPRENOLOL; PERINDOPRIL; PINDOLOL; PLACEBO; PROPRANOLOL; RAMIPRIL; RENIN INHIBITOR; TRANDOLAPRIL; TRIACYLGLYCEROL; VERAPAMIL;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; DEATH; DIABETES MELLITUS; DRUG WITHDRAWAL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LANGUAGE; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT; WEIGHT;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION;

EID: 72249106213     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M381     Document Type: Review

References (67)

1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827 DOI 10.1161/HYPERTENSIONAHA.108.113357
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2571 DOI 10.1001/jama.289.19.2560
3. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 1977;237:255-261 DOI 10.1001/jama.1977.03270300059008
4. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980;140:1280-1285 DOI 10.1001/archinte.1980.00330210028018 (Pubitemid 10008726)
5. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984;144:1045-1057 DOI 10.1001/archinte.1984.00350170211032 (Pubitemid 14145217)
6. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183 DOI 10.1001/archinte.1993.00410020010002
7. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446 DOI 10.1001/archinte.1997.00440420033005
8. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the β-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:379-392 DOI 10.1097/00004872-198508000-00011
9. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104. DOI: 10.1136/bmj.291.6488. 97
10. Coope J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ 1986;293:1145-1151 DOI 10.1136/bmj.293.6555.1145 (Pubitemid 16008923)
11. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-412 DOI 10.1136/bmj.304.6824.405
12. Dahlof B, Hansson L, Lindholm LH, Schersten B, Ekbom T, Wester PO. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens 1993;15:925-939 DOI 10.3109/10641969309037082 (Pubitemid 23344569)
13. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-572 DOI 10.1097/00004872-198710000-00009
14. Wilkstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259:1876-1882 DOI 10.1001/jama.259.13. 1976
15. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992;5:182S-9S.
16. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720
17. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: result from the AASK trial. JAMA 2002;288:2421-2431 DOI 10.1001/jama.288.19.2421 (Pubitemid 35340538)
18. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003. DOI 10.1016/S0140-6736(02)08089-3 (Pubitemid 34286536)
19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816 DOI 10.1001/jama.290.21.2805
20. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906. DOI 10.1016/S0140-6736(05)67185-1 (Pubitemid 41265663)
21. Black HR, Elliot WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-2082 DOI 10.1001/jama.289.16.2073 (Pubitemid 37430209)
22. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-616 DOI 10.1016/S0140-6736(98)05012-0 (Pubitemid 29087980)
23. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756 DOI 10.1016/S0140-6736(99)10327-1
24. Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-365 DOI 10.1016/S0140-6736(00)02526-5 (Pubitemid 30487491)
25. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745 DOI 10.1001/jama.1997.03540330061036
26. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-1907 DOI 10.1001/jama.279.23.1903 (Pubitemid 28299288)
27. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ 1999;161:25-32.
28. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689 DOI 10.1016/S0140-6736(04)17355-8
29. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553 DOI 10.1016/S0140-6736(05)67573-3. (Pubitemid 41540112)
30. Bradley HA, Wiysonge CS, Volmink J, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24: 2131-2141 DOI 10.1097/01.hjh.0000249685.58370.28 (Pubitemid 44611017)
31. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174:1737-1742 DOI 10.1503/cmaj.060110 (Pubitemid 43893565)
32. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;1:CD002003. DOI 10.1002/14651858.CD002003.pub2
33. Dahlof B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? Blood Press 2007;16:6-12. DOI 10.1080/08037050701246386
34. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension. Insights from a meta-analysis. J Am Coll Cardiol 2008;52:1062-1072 DOI 10.1016/j.jacc.2008. 05.057
35. Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. CMAJ 2000;163:188-192 (Pubitemid 30625660)
36. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for initial treatment of hypertension: II. Results of long-term therapy. JAMA 1982; 248:2004-2011 DOI 10.1001/jama.1982.03330160052024
37. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-123 DOI 10.1016/j.amjhyper.2003.09.012 (Pubitemid 38125127)
38. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure- lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225 DOI 10.1161/CIRCULATIONAHA.105.595496 (Pubitemid 43754247)
39. Lund-Johansen P. Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1979;1:487-495 (Pubitemid 10189992)
40. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
41. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46 DOI 10.1016/S0002-9343(03)00158-X (Pubitemid 36831120)
42. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized doubleblind studies. JAMA 1996;275:1507-1513 DOI 10.1001/jama.1996.03530430051039 (Pubitemid 26140765)
43. Schulman SP, Weiss JL, Becker LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990;322:1350-1356 (Pubitemid 20154478)
44. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008;21:500-508 DOI 10.1038/ajh.2008.16 (Pubitemid 351589672)
45. Reneland R, Alvarez E, Andersson P-E, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000;14:175-180 DOI 10.1038/sj.jhh.1000964 (Pubitemid 30153630)
46. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10.
47. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005;23:1777-1781 (Pubitemid 41830411)
48. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004;22:1453-1458 DOI 10.1097/01.hjh.0000133732.24501.9e
49. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989;298:1152-1157 DOI 10.1136/bmj.298.6681.1152 (Pubitemid 19121350)
50. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunhall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989;7:551-559 DOI 10.1097/00004872-198907000-00006 (Pubitemid 19189577)
51. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-2236 DOI 10.1001/jama.292.18. 2227 (Pubitemid 39473160)
52. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: betaadrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001;37:250-254 (Pubitemid 32199083)
53. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-207 DOI 10.1016/S0140-6736(07)60108-1 (Pubitemid 46111014)
54. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. The Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-912 DOI 10.1056/NEJM200003303421301
55. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43: 963-969 DOI 10.1161/01.HYP.0000125726.92964.ab (Pubitemid 38579899)
56. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002;20:2099-2110 DOI 10.1097/00004872-200211000-00001
57. Prichard BNC, Cruickshank JM, Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 2001;10:366-386 DOI 10.1080/080370501753400665
58. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990;120:166-171 DOI 10.1016/0002-8703(90)90174-V (Pubitemid 20210241)
59. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993;94:181-187 DOI 10.1016/0002-9343(93)90181-N (Pubitemid 23046444)
60. Broeders MAW, Doevendans PA, Bekkers BCAM, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta2-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-684
61. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-2752 DOI 10.1161/01.CIR.0000066912.58385.DE (Pubitemid 36667251)
62. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1734 (Pubitemid 29290470)
63. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34. DOI 10.1016/S0735-1097(97)00104-6 (Pubitemid 27357123)
64. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:L1927-36. DOI 10.1001/jama.281.20.1927
65. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-357 DOI 10.1016/S1388-9842(01)00144-1 (Pubitemid 32895844)
66. Campbell NR, Khan NA, Hill MD, et al. 2009 Canadian Hypertension Education Program recommendations: the scientific summary-an annual update. Can J Cardiol 2009;25:271-277
67. National Collaborating Centre for Chronic Conditions. Hypertension: management in adults in primary care: pharmacological update. London: Royal College of Physicians. www.nice.org.uk/nicemedia/pdf/ HypertensionGuide.pdf (accessed 2009 Jun 23).